Target enrollment in the chronic cohort of our Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury ...

NervGen Pharma (TSE:NGEN) has released an update. NervGen Pharma is nearing the completion of enrollment for its Phase 1b/2a clinical trial of ...

Vancouver, British Columbia--(Newsfile Corp. - November 7, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a ...

NervGen Pharma (TSE:NGEN) has released an update. NervGen Pharma, a clinical-stage biotech company, is set to present at the Stifel 2024 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

As of 08:04 CET. Market open. Vancouver, British Columbia--(Newsfile Corp. - November 7, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to ...

Vancouver, British Columbia--(Newsfile Corp. - November 7, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative ...

Featured here, the Balance Sheet for NervGen Pharma Corp, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 10 period ...